Veracyte Q2 Revenues up 71 Percent; Agrees to Amend Genyzme Deal | GenomeWeb

NEW YORK (GenomeWeb) – Veracyte announced after the close of the market on Wednesday that its revenues for the second quarter increased 71 percent year over year, but still fell short of the consensus analysts' estimate.

It also said that it and Genzyme have agreed to amend their co-promotion agreement reached in early 2012.

The South San Francisco, Calif.-based firm said that for the three months ended June 30, revenues reached $8.7 million, compared to $5.1 million in the year-ago period. On average, Wall Street had expected revenues of $9.4 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: researchers identify the characteristic genomic features of clear cell renal cell carcinoma, and more.

A technology that has the potential to make species go extinct could be used against the Zika virus. 

University of the Republic postdoc Victor Morais says researchers should be careful of the open access journals they choose to publish in.

If science funding agencies can talk tough about sexual harassers, shouldn't they also put their talk into action?